Skip to main content
SpringerLink
Log in

Controversies in Contraception

  • Chapter
The Handbook of Contraception

Part of the book series: Current Clinical Practice ((CCP))

  • 2044 Accesses

Abstract

Few areas of medical care are as fraught with controversy as female contraception. Most debates in the lay community stem from divergent political and religious standpoints, with such discussions invariably deliberate on women’s rights to control their own fertility and the availability of safe, effective, and reversible methods. Within the medical community, debates mostly revolve around the safety of highly effective hormonal and intrauterine methods, with such disputes being frequently used as fuel in the overarching socio-political deliberations. Health care providers must be familiar with the evidence behind the controversies. Women often present with preformed ideas about the safety or risks of taking certain contraceptives. These preconceptions can lead to reluctance to accept contraceptive methods that may be optimal for a particular woman and thus result in an unintended and unplanned pregnancy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–27.

    Article  Google Scholar 

  2. Rosenblatt KA, Gao DL, Ray RM, et al. Oral contraceptives and the risk of all cancers combined and site-specific cancers in Shanghai. Cancer Causes Control. 2009;20:27–34.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346:2025–32.

    Article  CAS  PubMed  Google Scholar 

  4. Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception. 2010;82:221–9.

    Article  PubMed  Google Scholar 

  5. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Hormonal contraceptives, progestogens only. In: Hormonal contraception and post-menopausal hormonal therapy; IARC monographs on the evaluation of carcinogenic risks to humans, vol 72. Lyon: IARC Press; 1999, pp. 339–97. ISBN 92-832-1272-X.

    Google Scholar 

  6. Backman T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol. 2005;106:813–7.

    Article  PubMed  Google Scholar 

  7. Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception. 2011;83:211–7.

    Article  CAS  PubMed  Google Scholar 

  8. Shapiro S, Rosenberg L, Hoffman M, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemio. 2000;151:396–403.

    Article  CAS  Google Scholar 

  9. Strom BL, Berlin JA, Weber AL, et al. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception. 2004;69:353–60.

    Article  CAS  PubMed  Google Scholar 

  10. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–6.

    Article  CAS  PubMed  Google Scholar 

  11. Metcalfe KA, Lynch HT, Ghadirian P, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005;96:222–6.

    Article  CAS  PubMed  Google Scholar 

  12. Silvera SA, Miller AB, Rohan TE. Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study. Cancer Causes Control. 2005;16:1059–63.

    Article  PubMed  Google Scholar 

  13. Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002;94:1773–9.

    Article  CAS  PubMed  Google Scholar 

  14. Haile RW, Thomas DC, McGuire V, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev. 2006;15:1863–70.

    Article  CAS  PubMed  Google Scholar 

  15. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303–14.

    Article  Google Scholar 

  16. Grenader T, Peretz T, Lifchitz M, Shavit L. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use. Breast. 2005;14:264–8.

    Article  PubMed  Google Scholar 

  17. Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther. 2011;11:1197–207.

    Article  CAS  PubMed  Google Scholar 

  18. Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31:4188–98.

    Article  CAS  PubMed  Google Scholar 

  19. Centers for Disease Control and Prevention. Medical eligibility criteria for contraceptive use. MMWR Early Release 2010;59.

    Google Scholar 

  20. Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam PA. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril. 2008;90:17–22.

    Article  CAS  PubMed  Google Scholar 

  21. Burkman RT. Venous thromboembolism and oral contraceptives: current status and clinical implications. Treat Endocrinol. 2002;1:143–7.

    Article  CAS  PubMed  Google Scholar 

  22. Shulman LP, Goldzieher JW, Minkin MJ, Sulak PJ, Thorneycroft I. Oral contraceptives and venous thromboembolic events. J Reprod Med. 2003;48:306–7.

    PubMed  Google Scholar 

  23. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.

    Article  PubMed Central  PubMed  Google Scholar 

  24. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies. J Fam Plann Reprod Health Care. 2010;36:33–8.

    Article  PubMed  Google Scholar 

  26. American Congress of Obstetricians and Gynecologists. Risk of venous thromboembolism among users of drospirenone-containing oral contraceptive pills. ACOG Committee Opinion #540, 2012.

    Google Scholar 

  27. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011;342:d2151.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ. 2011;342:d2139.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75:344–54.

    Article  CAS  PubMed  Google Scholar 

  30. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol. 2007;110:587–93.

    Article  CAS  PubMed  Google Scholar 

  31. Dinger J, Bardenheuer K, Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception. 2014;89:253–63.

    Article  CAS  PubMed  Google Scholar 

  32. Mohllajee AP, Curtis KM, Martins SL, Peterson HB. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. Contraception. 2006;73:166–78.

    Article  CAS  PubMed  Google Scholar 

  33. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception. 2003;68:75–87.

    Article  CAS  PubMed  Google Scholar 

  34. Depo-Provera Prescribing Information. Pfizer Inc. http://labeling.pfizer.com/ShowLabeling.aspx?id=522 . Accessed June 18, 2015.

  35. Mishell Jr DR. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med. 1996;41:381–90.

    CAS  PubMed  Google Scholar 

  36. Gbolade BA. Depo-Provera and bone density. J Fam Plann Reprod Health Care. 2002;28:7–11.

    Article  PubMed  Google Scholar 

  37. ACOG Committee Opinion #602. Depot Medrozyprogesterone Acetate and Bone Effects.

    Google Scholar 

  38. Paschall S, Kaunitz AM. Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians. Contraception. 2008;78:370–6.

    Article  CAS  PubMed  Google Scholar 

  39. Watson KC, Lentz MJ, Cain KC. Associations between fracture incidence and use of depot medroxyprogesterone acetate and anti-epileptic drugs in women with developmental disabilities. Womens Health Issues. 2006;16:346–52.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab. 2010;95:4909–16.

    Article  CAS  PubMed  Google Scholar 

  41. Lanza LL, McQuay LJ, Rothman KJ, et al. Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture. Obstet Gynecol. 2013;121:593–600.

    Article  CAS  PubMed  Google Scholar 

  42. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology. 2002;13:581–7.

    Article  PubMed  Google Scholar 

  43. Clark MK, Sowers M, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2006;86:1466–74.

    Article  CAS  PubMed  Google Scholar 

  44. Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception. 2006;74:90–9.

    Article  CAS  PubMed  Google Scholar 

  45. Harel Z, Johnson CC, Gold MA, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception. 2010;81:281–91.

    Article  CAS  PubMed  Google Scholar 

  46. World Health Organization. Technical consultation on the effects of hormonal contraception on bone health. Geneva: WHO; 2007.

    Google Scholar 

  47. Speroff L, Darney PD. A clinical guide for contraception. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.

    Google Scholar 

  48. Jones J, Mosher W, Daniels K. Current contraceptive use in the United States, 2006–2010, and changes in patterns of use since 1995. Natl Health Stat Rep. 2012;18(60):1–25.

    Google Scholar 

  49. Clifton D, Kaneda T, Ashford L. Family planning worldwide 2008 data sheet. Washington, DC: Population Reference Bureau; 2008, p. 15.

    Google Scholar 

  50. Daling JR, Weiss NS, Metch BJ, et al. Primary tubal infertility in relation to the use of an intrauterine device. N Engl J Med. 1985;312:937–41.

    Article  CAS  PubMed  Google Scholar 

  51. Cramer DW, Schiff I, Schoenbaum SC, et al. Tubal infertility and the intrauterine device. N Engl J Med. 1985;312:941–7.

    Article  CAS  PubMed  Google Scholar 

  52. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzman-Rodriguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001;345:561–7.

    Article  CAS  PubMed  Google Scholar 

  53. Pyorala T, Allonen H, Nygren KG, Nielsen NC, Luukkainen T. Return of fertility after the removal of Nova T or copper T 200. Contraception. 1982;26:113–20.

    Article  CAS  PubMed  Google Scholar 

  54. Skjeldestad F, Bratt H. Fertility after complicated and non-complicated use of IUDs. A controlled prospective study. Adv Contracept. 1988;4:179–84.

    Article  CAS  PubMed  Google Scholar 

  55. Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility – follow-up after participation in a randomized clinical trial. Contraception. 2007;75:88–92.

    Article  PubMed  Google Scholar 

  56. Rioux JE, Cloutier D, Dupont P, Lamonde D. Pregnancy after IUD use. Adv Contracept. 1986;2:185–92.

    Article  CAS  PubMed  Google Scholar 

  57. Sivin I, Stern J, Diaz S, et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. Am J Obstet Gynecol. 1992;166:1208–13.

    Article  CAS  PubMed  Google Scholar 

  58. Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception. 1992;46:575–84.

    Article  CAS  PubMed  Google Scholar 

  59. Randic L, Vlasic S, Matrljan I, Waszak CS. Return to fertility after IUD removal for planned pregnancy. Contraception. 1985;32:253–9.

    Article  CAS  PubMed  Google Scholar 

  60. Sandmire HF. Fertility after intrauterine device discontinuation. Adv Contracept. 1986;2:327–35.

    Article  CAS  PubMed  Google Scholar 

  61. Wilson JC. A prospective New Zealand study of fertility after removal of copper intrauterine contraceptive devices for conception and because of complications: a four-year study. Am J Obstet Gynecol. 1989;160:391–6.

    Article  CAS  PubMed  Google Scholar 

  62. Mansour D, Gemzell-Danielsson K, Inki P, Jensen JT. Fertility after discontinuation of contraception: a comprehensive review of the literature. Contraception. 2011;84:465–77.

    Article  CAS  PubMed  Google Scholar 

  63. Delbarge W, Batar I, Bafort M, et al. Return to fertility in nulliparous and parous women after removal of the GyneFix intrauterine contraceptive system. Eur J Contracept Reprod Health Care. 2002;7:24–30.

    Article  CAS  PubMed  Google Scholar 

  64. Tadesse E. Return of fertility after an IUD removal for planned pregnancy: a six year prospective study. East Afr Med J. 1996;73:169–71.

    CAS  PubMed  Google Scholar 

  65. Belhadj H, Sivin I, Diaz S, et al. Recovery of fertility after use of the levonorgestrel 20 mcg/d or Copper T 380 Ag intrauterine device. Contraception. 1986;34:261–7.

    Article  CAS  PubMed  Google Scholar 

  66. Cronin M, Schellschmidt I, Dinger J. Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives. Obstet Gynecol. 2009;114:616–22.

    Article  PubMed  Google Scholar 

  67. Wiegratz I, Mittmann K, Dietrich H, Zimmermann T, Kuhl H. Fertility after discontinuation of treatment with an oral contraceptive containing 30 microg of ethinyl estradiol and 2 mg of dienogest. Fertil Steril. 2006;85:1812–9.

    Article  CAS  PubMed  Google Scholar 

  68. Funk S, Miller MM, Mishell Jr DR, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception. 2005;71:319–26.

    Article  CAS  PubMed  Google Scholar 

  69. Paulen ME, Curtis KM. When can a woman have repeat progestogen-only injectables – depot medroxyprogesterone acetate or norethisterone enantate? Contraception. 2009;80:391–408.

    Article  CAS  PubMed  Google Scholar 

  70. Jain J, Dutton C, Nicosia A, Wajszczuk C, Bode FR, Mishell Jr DR. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception. 2004;70:11–8.

    Article  CAS  PubMed  Google Scholar 

  71. Toh YC, Jain J, Rahnny MH, Bode FR, Ross D. Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women. Clinical therapeutics. 2004;26:1845–54.

    Article  CAS  PubMed  Google Scholar 

  72. Garza-Flores J, Cardenas S, Rodriguez V, Cravioto MC, Diaz-Sanchez V, Perez-Palacios G. Return to ovulation following the use of long-acting injectable contraceptives: a comparative study. Contraception. 1985;31:361–6.

    Article  CAS  PubMed  Google Scholar 

  73. Bassol S, Garza-Flores J, Cravioto MC, et al. Ovarian function following a single administration of depo-medroxyprogesterone acetate (DMPA) at different doses. Fertil Steril. 1984;42:216–22.

    CAS  PubMed  Google Scholar 

  74. Lan PT, Aedo AR, Landgren BM, Johannisson E, Diczfalusy E. Return of ovulation following a single injection of depo-medroxyprogesterone acetate: a pharmacokinetic and pharmacodynamic study. Contraception. 1984;29:1–18.

    Article  CAS  PubMed  Google Scholar 

  75. Fotherby K, Koetsawang S, Mathrubutham M. Pharmacokinetic study of different doses of Depo Provera. Contraception. 1980;22:527–36.

    Article  CAS  PubMed  Google Scholar 

  76. Fotherby K, Saxena BN, Shrimanker K, et al. A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate. Fertil Steril. 1980;34:131–9.

    CAS  PubMed  Google Scholar 

  77. Saxena BN, Dusitsin N, Tankeyoon M, Chaudhury RR. Return of ovulation after the cessation of depot-medroxy progesterone acetate treatment in Thai women. J Med Assoc Thai. 1980;63:66–9.

    CAS  PubMed  Google Scholar 

  78. Steiner MJ, Kwok C, Stanback J, et al. Injectable contraception: what should the longest interval be for reinjections? Contraception. 2008;77:410–4.

    Article  CAS  PubMed  Google Scholar 

  79. Pardthaisong T. Return of fertility after use of the injectable contraceptive Depo Provera: up-dated data analysis. J Biosoc Sci. 1984;16:23–34.

    CAS  PubMed  Google Scholar 

  80. Schwallie PC, Assenzo JR. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception. 1974;10:181–202.

    Article  CAS  PubMed  Google Scholar 

  81. Centers for Disease Control and Prevention. Selected practice recommendations for contraceptive use. MMWR. 2013;62:20–1.

    Google Scholar 

  82. Turner R. Most British women use reliable contraceptive methods, but many fear health risks from use. Fam Plann Perspect. 1994;26:183–4.

    Article  Google Scholar 

  83. Emans SJ, Grace E, Woods ER, Smith DE, Klein K, Merola J. Adolescents’ compliance with the use of oral contraceptives. JAMA. 1987;257:3377–81.

    Article  CAS  PubMed  Google Scholar 

  84. Le MG, Laveissiere MN, Pelissier C. Factors associated with weight gain in women using oral contraceptives: results of a French 2001 opinion poll survey conducted on 1665 women. Gynecol Obstet Fertil. 2003;31:230–9.

    Article  CAS  PubMed  Google Scholar 

  85. Oddens BJ. Women’s satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning, and sterilization among 1466 women. Contraception. 1999;59:277–86.

    Article  CAS  PubMed  Google Scholar 

  86. Moore LL, Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception. 1995;52:215–9.

    Article  CAS  PubMed  Google Scholar 

  87. Rosenberg M. Weight change with oral contraceptive use and during the menstrual cycle. Results of daily measurements. Contraception. 1998;58:345–9.

    Article  CAS  PubMed  Google Scholar 

  88. Gupta S. Weight gain on the combined pill – is it real? Hum Reprod Update. 2000;6:427–31.

    Article  CAS  PubMed  Google Scholar 

  89. Gallo MF, Lopez LM, Grimes DA, Carayon F, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2014;1, CD003987.

    PubMed  Google Scholar 

  90. Coney P, Washenik K, Langley RG, DiGiovanna JJ, Harrison DD. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception. 2001;63:297–302.

    Article  CAS  PubMed  Google Scholar 

  91. Goldzieher JW, Moses LE, Averkin E, Scheel C, Taber BZ. A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertil Steril. 1971;22:609–23.

    CAS  PubMed  Google Scholar 

  92. Procter-Gray E, Cobb KL, Crawford SL, et al. Effect of oral contraceptives on weight and body composition in young female runners. Med Sci Sports Exerc. 2008;40:1205–12.

    Article  CAS  PubMed  Google Scholar 

  93. Cobb KL, Bachrach LK, Sowers M, et al. The effect of oral contraceptives on bone mass and stress fractures in female runners. Med Sci Sports Exerc. 2007;39:1464–73.

    Article  CAS  PubMed  Google Scholar 

  94. Sibai BM, Odlind V, Meador ML, Shangold GA, Fisher AC, Creasy GW. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril. 2002;77:S19–26.

    Article  PubMed  Google Scholar 

  95. Bonny AE, Secic M, Cromer BA. A longitudinal comparison of body composition changes in adolescent girls receiving hormonal contraception. J Adolesc Health. 2009;45:423–5.

    Article  PubMed Central  PubMed  Google Scholar 

  96. Tankeyoon M, Dusitsin N, Poshyachinda V, Larsson-Cohn U. A study of glucose tolerance, serum transaminase and lipids in women using depot-medroxyprogesterone acetate and a combination-type oral contraceptive. Contraception. 1976;14:199–214.

    Article  CAS  PubMed  Google Scholar 

  97. Tuchman LK, Huppert JS, Huang B, Slap GB. Adolescent use of the monthly contraceptive injection. J Pedatr Adolesc Gynecol. 2005;18:255–60.

    Article  Google Scholar 

  98. Westhoff C, Jain JK, Milsom I, Ray A. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL. Contraception. 2007;75:261–7.

    Article  CAS  PubMed  Google Scholar 

  99. Castle WM, Sapire KE, Howard KA. Efficacy and acceptability of injectable medroxyprogesterone. A comparison of 3-monthly and 6-monthly regimens. South Afr Med J. 1978;53:842–5.

    CAS  Google Scholar 

  100. Espey E, Steinhart J, Ogburn T, Qualls C. Depo-provera associated with weight gain in Navajo women. Contraception. 2000;62:55–8.

    Article  CAS  PubMed  Google Scholar 

  101. World Health Organization. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report. Contraception. 1983;28:1–20.

    Article  Google Scholar 

  102. Taneepanichskul S, Reinprayoon D, Jaisamrarn U. Effects of DMPA on weight and blood pressure in long-term acceptors. Contraception. 1999;59:301–3.

    Article  CAS  PubMed  Google Scholar 

  103. Pantoja M, Medeiros T, Baccarin MC, Morais SS, Bahamondes L, Fernandes AM. Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive. Contraception. 2010;81:107–11.

    Article  CAS  PubMed  Google Scholar 

  104. Dal’ava N, Bahamondes L, Bahamondes MV, Bottura BF, Monteiro I. Body weight and body composition of depot medroxyprogesterone acetate users. Contraception. 2014;90(2):182–7.

    Article  PubMed  Google Scholar 

  105. Curtis KM, Ravi A, Gaffield ML. Progestogen-only contraceptive use in obese women. Contraception. 2009;80:346–54.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Section of Family Planning and Contraception, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

    Jessica W. Kiley MD, MPH

  2. Department of Obstetrics and Gynecology, Division of Clinical Genetics, Feinberg School of Medicine, Northwestern University, 250 E. Superior Street, Room 05-2174, Chicago, IL, 60611, USA

    Lee P. Shulman MD

Authors
  1. Jessica W. Kiley MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lee P. Shulman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jessica W. Kiley MD, MPH .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Keck Medical School at the University of Southern California, Los Angeles, California, USA

    Donna Shoupe

  2. Department of Obstetrics and Gynecology, Keck School of Medicine University of Southern California, LOS ANGELES, California, USA

    Daniel R. Mishell, Jr.

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Kiley, J.W., Shulman, L.P. (2016). Controversies in Contraception. In: Shoupe, D., Mishell, Jr., D. (eds) The Handbook of Contraception. Current Clinical Practice. Humana Press, Cham. https://doi.org/10.1007/978-3-319-20185-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20185-6_15

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-20184-9

  • Online ISBN: 978-3-319-20185-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation